menu search

Catalyst (cprx) skyrockets 110% over a year: here's why

Catalyst's (CPRX) stock price has more than doubled in the past year, driven by its sole marketed drug, Firdapse, approved for the treatment of Lamber...

March 10, 2022, 12:47 pm

Intra-cellular; long-term to own with a few fda approvals and ability to expand

CAPLYTA has been approved by the FDA for the treatment of adults with schizophrenia and ...

March 8, 2022, 3:09 pm

Why alpine immune's shares are falling today

The FDA has placed a partial clinical hold on Alpine Immune Sciences Inc's (NASDAQ: ALPN) NEON-2 trial evaluating davoceticept (ALPN-202) in combi...

March 7, 2022, 12:13 pm

Why alpine immune's shares are falling today

The FDA has placed a partial clinical hold on Alpine Immune Sciences Inc's (NASDAQ: ALPN) NEON-2 trial evaluating davoceticept (ALPN-202) in combi...

March 7, 2022, 12:13 pm

Why alpine immune's shares are falling today

The FDA has placed a partial clinical hold on Alpine Immune Sciences Inc's (NASDAQ: ALPN) NEON-2 trial evaluating davoceticept (ALPN-202) in combi...

March 7, 2022, 12:13 pm

What to expect from urban outfitters' stock post q4?

Urban Outfitters, a lifestyle retailer focusing on young adults and teenagers, is scheduled to report i...

February 28, 2022, 2:00 pm

What to expect from urban outfitters' stock post q4?

Urban Outfitters, a lifestyle retailer focusing on young adults and teenagers, is scheduled to report i...

February 28, 2022, 2:00 pm

What to expect from urban outfitters' stock post q4?

Urban Outfitters, a lifestyle retailer focusing on young adults and teenagers, is scheduled to report i...

February 28, 2022, 2:00 pm

Moderna's stock gains 3% as it moves forward with phase 3 clinical trial for rsv vaccine candidate

Shares of Moderna Inc. MRNA, +2.82% gained 3.0% in trading on Monday after the company said it began a Phase 3 clinical trial evaluating its respirato...

February 22, 2022, 10:30 am

Moderna's stock gains 3% as it moves forward with phase 3 clinical trial for rsv vaccine candidate

Shares of Moderna Inc. MRNA, +2.82% gained 3.0% in trading on Monday after the company said it began a Phase 3 clinical trial evaluating its respirato...

February 22, 2022, 10:30 am

Moderna's stock gains 3% as it moves forward with phase 3 clinical trial for rsv vaccine candidate

Shares of Moderna Inc. MRNA, +2.82% gained 3.0% in trading on Monday after the company said it began a Phase 3 clinical trial evaluating its respirato...

February 22, 2022, 10:30 am

Fda approves agios' mitapivat as first disease-modifying therapy for genetic blood disorder

The FDA approved Agios Pharmaceuticals Inc's (NASDAQ: AGIO) Pyrukynd (mitapivat) for hemolytic anemia in ad...

February 18, 2022, 5:41 am

Fda approves agios' mitapivat as first disease-modifying therapy for genetic blood disorder

The FDA approved Agios Pharmaceuticals Inc's (NASDAQ: AGIO) Pyrukynd (mitapivat) for hemolytic anemia in ad...

February 18, 2022, 5:41 am

Fda approves agios' mitapivat as first disease-modifying therapy for genetic blood disorder

The FDA approved Agios Pharmaceuticals Inc's (NASDAQ: AGIO) Pyrukynd (mitapivat) for hemolytic anemia in ad...

February 18, 2022, 5:41 am

Canada authorizes novavax's non-mrna covid vaccine for use in adults

Nuvaxovid, a protein-based Covid vaccine, could help reduce hesitancy among people suspicious of mRNA vaccine technology....

February 17, 2022, 1:07 pm

Canada authorizes novavax's non-mrna covid vaccine for use in adults

Nuvaxovid, a protein-based Covid vaccine, could help reduce hesitancy among people suspicious of mRNA vaccine technology....

February 17, 2022, 1:07 pm

Canada authorizes novavax's non-mrna covid vaccine for use in adults

Nuvaxovid, a protein-based Covid vaccine, could help reduce hesitancy among people suspicious of mRNA vaccine technology....

February 17, 2022, 1:07 pm

Global blood therapeutics' oxbryta scores european approval for sickle cell disease

The European Commission (EC) has approved Global Blood Therapeutics Inc's (NASDAQ: GBT) Oxbryta (voxelotor) for hemolytic anemia due to sickle cell...

February 16, 2022, 9:41 am

Global blood therapeutics' oxbryta scores european approval for sickle cell disease

The European Commission (EC) has approved Global Blood Therapeutics Inc's (NASDAQ: GBT) Oxbryta (voxelotor) for hemolytic anemia due to sickle cell...

February 16, 2022, 9:41 am

Global blood therapeutics' oxbryta scores european approval for sickle cell disease

The European Commission (EC) has approved Global Blood Therapeutics Inc's (NASDAQ: GBT) Oxbryta (voxelotor) for hemolytic anemia due to sickle cell...

February 16, 2022, 9:41 am


Search within

Pages Search Results: